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INTRODUCTION
Multiple sclerosis (MS) is a heteroge-
neous inflammatory demyelinating dis-
ease of the central nervous system and
the most common cause of neurological
disability in young adults (1,2). Essen-
tially all treatments, established or in de-
velopment, focus on immunological tar-
gets to modify disease course and reduce
relapse rates (3). In contrast, recombinant
human erythropoietin (EPO) and EPO
variants may provide a neuroprotective/
neuroregenerative treatment strategy for
MS (reviewed in [4]).
In fact, several preclinical studies of
experimental autoimmune encephalo -
myelitis (EAE), the most commonly used
animal model for MS, showed that EPO
delayed disease onset, reduced neurolog-
ical scores, improved electrophysiologi-
cal and histological readouts and attenu-
ated inflammatory cytokine production
(5–16; reviewed in [4] and [17]). A first
small exploratory open-label study in MS
included patients with primary or sec-
ondary chronic progressive disease.
These MS patients were treated with ei-
ther high-dose (48,000 IU intravenously)
or low-dose (8,000 IU intravenously)
EPO, and safety issues and potential effi-
cacy were evaluated (18). High-dose EPO
treatment was well tolerated and re-
sulted in improvement of motor and cog-
nitive performance. Interestingly, this
beneficial effect persisted for as long as
up to 6 months after cessation of EPO
 infusions (18).
High-dose peripherally applied EPO
was shown in humans and mouse to
penetrate an intact blood-brain barrier in
an amount sufficient to achieve neuro-
protective effects in the brain (17,19). The
mechanisms of action of EPO underlying
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its neuroprotective/neuroregenerative
properties in EAE and MS, which share
an immunological etiology, are still sub-
ject to speculation and may involve anti-
inflammatory, antiapoptotic, antioxida-
tive and neurotrophic effects (reviewed
in [17] and [20]).
We wondered whether EPO would
also show neuroprotection in an etiologi-
cally different situation of even more
pronounced demyelination. Hence, we
used the copper chelator cuprizone,
which leads to almost complete demyeli-
nation of the corpus callosum. This
model permits focusing on demyelina-
tion without interfering T cell–mediated
immune-inflammatory components.
Considering the seemingly beneficial ef-
fects of EPO in chronic progressive MS
where acute immune-inflammatory
processes are replaced by smoldering
progression, we hypothesized that EPO
treatment would also alleviate the cupri-
zone-induced changes of neurological,
imaging and histological readouts.
MATERIALS AND METHODS
Animals
All experiments were approved by and
conducted in accordance with the regula-
tions of the local animal care and use
committee (Niedersächsisches Landesamt
für Verbraucherschutz und Lebensmittel-
sicherheit; AZ 33.11.42502-04-040/08). For
all experiments, male C57BL/6 mice were
used. They were housed in groups of five
in standard plastic cages and maintained
in a temperature-controlled environment
(21 ± 2°C) on a 12-h light/dark cycle with
food and water available ad libitum. Dur-
ing experiments, body weight was moni-
tored twice weekly.
Experimental Design
In a double-blind (for food and injec-
tions), placebo-controlled longitudinal
four-arm design, 8-wk old male C57BL/6
mice (n = 26 per group) were started on
cuprizone-containing (0.2%; Sigma-
Aldrich, Taufkirchen, Germany) or regu-
lar food (standard ground chow) for a
total of 6 wks. After 3 wks, mice were in-
jected every other day (11 injections in
total) with placebo (solvent control) or
EPO (5,000 IU/ kg body weight intraperi-
toneally; NeoRecormon, Roche, Basel,
Switzerland) up to the end of cuprizone
feeding (compare Figure 1A). Half of the
mice were exposed to behavioral testing,
MRI and histology immediately after ces-
sation of treatment, whereas the other
half were allowed a 3-wk treatment-free
recovery period before behavioral testing
and MRI.
It should be noted that preliminary ex-
periments performed with cuprizone-
 containing pellets instead of ground chow
failed to result in any demyelination, al-
though toxicological analysis of the pel-
lets had proven that cuprizone was intact
and active. This result may be due to the
necessity of a parallel intake of cuprizone
as fine powder via skin, airways and gut
for producing demyelination.
Behavioral Testing
Group size in all behavioral experi-
ments amounted to n = 13–26.
Rotarod. Rotarod is a relatively crude
test for motor function, gross coordina-
tion and motor learning and consists of a
rotating drum (Med Associates Inc., St.
Albans, VT, USA) that is accelerated
from 4 to 40 revolutions per minute over
the course of 5 min. Each mouse is
placed individually on the drum and the
latency of falling down from the drum is
recorded. To assess motor learning, the
rotarod test is repeated 24 and 48 h later.
Beam balance. Beam balance is a sensi-
tive test for (fine) motor coordination (bal-
ance) and vestibulomotor function. On
the first day, two habituation phases are
conducted where mice are placed on an
elevated horizontal beam (25 mm in di-
ameter, 59 cm in length), illuminated at
the start side and with a dark little cage
with bedding at the other end. With the
goal to enter the little cage, mice are first
placed directly in front of the cage (phase
1) and then in the middle of the beam
(phase 2). On the second day, all mice are
first habituated again on the 25-mm
beam, this time being positioned on the il-
luminated start. This forces them to cross
the whole beam for entering the little
cage. For the following test, mice are
placed on the start side of a 10-mm beam,
and the time needed to pass the beam is
recorded. On the third day, mice are again
first put on the 25-mm beam and then
switched onto an 8-mm beam for cross-
ing-time measurement. If a mouse falls
down, the test is repeated (maximally
three trials/mouse). If all trials fail, a cut-
off time of 60 s is used for calculations
(average time in a healthy mouse
amounts to <8 s). The results are calcu-
lated as duration on the beam in percent-
age of placebo control.
MRI Analysis
Upon completion of the behavioral
analyses, six mice per group at both week
6 and 9 were studied by MRI. Animals
were anesthetized by 1–1.5% isoflurane in
a mixture of oxygen and ambient air and
positive ventilated via endotracheal tube.
A 3D Fast Low-Angle Shot (FLASH) MRI
(repetition time [TR]/echo time [TE] =
14.9/3.9 ms, 45 min each) was performed
at 9.4T (Bruker Biospin, Ettlingen, Ger-
many) with 110-μm isotropic spatial reso-
lution using a four-element phased-array
surface coil (Bruker Biospin) for signal re-
ception. Maps of T1 relaxation time were
calculated from T1-weighted (flip angle
12°) and proton-density weighted
datasets (flip angle 5°). In addition, mag-
netization transfer-weighted images were
obtained by off-resonance irradiation (fre-
quency offset 3 kHz, Gaussian pulse, du-
ration 3.5 ms, flip angle 135°) to calculate
the percent magnetization transfer ratio
(%MTR). Brain volume (total brain, brain
matter, hippocampi, ventricles) was de-
termined by manual segmentation using
Amira software (Visage Imaging GmbH,
Berlin, Germany). In addition, multislice
T2-weighted images were acquired with
use of a fast-spin echo MRI sequence
(TR/TE = 5,300/64 ms, 8 echoes, 26 sec-
tions) at an in-plane resolution of 80 μm
and a section thickness of 300 μm (21).
Preparation of Brain Tissue
Animals were anesthetized with 0.25%
tribromoethanol (Avertin; 0.125 mg/g
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 intraperitoneally) and perfused transcar-
dially with 0.9% saline followed by 4%
paraformaldehyde. Brains were re-
moved, fixed overnight at 4°C with 4%
parafor mal dehyde and placed in 30% su-
crose/ phosphate-buffered saline (PBS)
for cryoprotection. They were frozen on
liquid nitrogen. Whole mouse brains
were cut into 30-μm thick coronal sec-
tions on a cryostat (Leica, Wetzlar, Ger-
many) and kept in a storage solution
(25% ethylene glycol and 25% glycerol in
PBS).
Immunohistochemistry
For immunohistochemistry, serial coro-
nal sections, spaced at regular intervals
for each specific marker under investiga-
tion, were taken through the whole
brain. Free floating sections were washed
with PBS three times, mounted on Super
Frost microscopic slides, microwaved
three times in citrate buffer for 4 min and
incubated with 0.5% hydrogen peroxide
for 30 min to quench endogenous peroxi-
dases. They were permeabilized and
blocked for 1 h at room temperature with
5% normal serum of host species from
which respective secondary antibodies
were derived. Sections were incubated
with mouse anti-APC (CC-1; 1:200;
Merck, Darmstadt, Germany), rabbit
anti-IBA1 (1:1,000; Wako, Neuss, Ger-
many) and mouse anti-amyloid precur-
sor protein (APP; 1:850; Millipore,
Schwalbach, Germany) antibodies di-
luted in 3% normal serum and 0.5% Tri-
ton-X in PBS for 48 h at 4ºC. After three
washes with PBS, sections were incu-
bated with biotinylated secondary
 antibodies for 1.5 h. The staining was
 visualized by a peroxidase-labeled
avidin-biotin kit (Vector Laboratories,
Burlingame, CA, USA) and diaminoben-
zidine (Sigma-Aldrich, Taufkirchen, Ger-
many). Sections stained for APP were
counterstained with hematoxylin for
30 s. Slides were washed in PBS, air-
dried overnight, put into xylol and
cover-slipped using DePeX (Serva, Hei-
delberg, Germany).
Quantification of Cell Numbers
Digitized overlapping light micro-
scopic images (400× oil; Zeiss, Ober -
kochen, Germany) from the rostral
(bregma 1.10 to –0.10) and caudal
(bregma –0.94 to –2.46) region of the cor-
pus callosum (compare Figure 3A) were
fused to continuous images using Photo-
shop CS. Cell counts were performed
using ImageJ software. Cell numbers
were calculated per millimeter squared.
Intra- and inter-rater reliability of cell
counts was conducted for all parameters
and revealed highly significant correla-
tions (r > 0.98; P < 0.001).




For isolation of total RNA, two coronal
brain sections per mouse were used,
using the RNeasy FFPE kit (Qiagen,
Hilden, Germany). First-strand cDNA
was generated from total RNA using N6
random primers. The relative concentra-
tions of mRNAs of interest in different
cDNA samples were measured out of
Figure 1. Clinical readouts of toxic demyelination and influence of EPO treatment. (A) Ex-
perimental design of the double-blind (for food and injections) longitudinal four-arm
study. (B) Body weight curve over the experimental period shows a dramatic difference
between cuprizone- and regular diet–fed mice (P < 0.001) but no influence of EPO
(mean ± SD). (C) The hematocrit of mice is increased upon EPO at wk 6, independent of
cuprizone. (D, E) Rotarod performance of mice is unaffected by cuprizone and/or EPO.
(F) Beam balance performance at wk 6 is clearly compromised upon cuprizone and re-
sponds to EPO treatment. At wk 9, a remarkable recovery becomes evident. For all pan-
els: n = 6–26 (respective n number is always given in the bar); mean ± SEM is presented.
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three replicates using the threshold cycle
method (delta Ct) for each dilution and
were normalized to a normalization fac-
tor derived from levels of “housekeep-
ers,” glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), β-actin and
hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT1) mRNA, calculated with
geNorm_win_3.5 (22). Reactions were
performed using the SYBR green PCR
master mix (ABgene, Foster City, CA,
USA) according to the protocol of the
manufacturer. Cycling was done for
2 min at 50°C, followed by denaturation
at 95°C for 10 min. The amplification
was carried out with 45 cycles of 95°C
for 15 s and 60°C for 60 s. The specificity
of each primer pair was controlled with a
melting curve analysis. For qPCR, the
following primers were used: mouse
 interleukin-1α (IL-1α) forward: 5′-TCA
ACC AAA CTA TAT ATC AGG ATG
TGG-3′, reverse: 5′-CGA GTA GGC ATA
CAT GTC AAA TTT TAC-3′; mouse in-
terleukin-1β (IL-1β) forward: 5′-AAG
GGC TGC TTC CAA ACC TTT GAC-3′,
reverse: 5′-ATA CTG CCT GCC TGA
AGC TCT TGT-3′; mouse transforming
growth factor-β (TGF-β) forward: 5′-TGA
CGT CAC TGG AGT TGT ACG-3′, re-
verse: 5′-GGT TCA TGT CAT GGA TGG
TGC-3′; mouse complement component
1, q subcomponent, A chain (C1qA) for-
ward: 5′-CGG GTC TCA AAG GAG
AGA GA-3′, reverse: 5′-CCT TTA AAA
CCT CGG ATA CCA GT-3′; mouse trig-
gering receptor expressed on myeloid
cells-2 (Trem-2) forward: 5′-ACA GCA
CCT CCA GGA ATC AAG-3′, reverse:
5′-CCA CAG CCC AGA GGA TGC-3′;
mouse GAPDH forward: 5′- CAA TGA
ATA CGG CTA CAG CAA C-3′, reverse:
5′-TTA CTC CTT GGA GGC CAT GT-3′;
mouse β-actin forward: 5′-CTT CCT CCC
TGG AGA AGA GC-3′, reverse: 5′- ATG
CCA CAG GAT TCC ATA CC-3′; mouse
HPRT1 forward: 5′-GCT TGC TGG TGA
AAA GGA CCT CTC GAA G-3′, reverse:
5′-ATG CCC TTG ACT ATA ATG AGT
ACT TCA GGG-3′.
Statistical Analysis
Data were compared using a one-
tailed Mann-Whitney U test. Significance
level was set to P ≤ 0.05. Data are repre-
sented as mean ± standard error of the
mean (SEM) unless otherwise stated. Sta-
tistical software used included Prism5
(GraphPad Software, San Diego, CA,
USA) and SPSS for Windows version
17.0 (https://www.spss.com/de). (Note:
The experimenters performing the exper-
iments and data analyses were not aware
of any group assignment of individual
mice [“completely blinded”]).
RESULTS
Study Design and Basic Readouts
Under Cuprizone and EPO
In a double-blind (for food and injec-
tions) placebo-controlled longitudinal
four-arm design, 8-wk-old C57BL/6 mice
(n = 26 per group) were started on
 cuprizone-containing (0.2%) or regular
food (ground chow) for a total of 6 wks.
After 3 wks, mice were injected every
other day with placebo or EPO
(5,000 IU/ kg body weight intraperi-
toneally) up to the end of cuprizone feed-
ing (study design shown in Figure 1A).
Already within the first week, cuprizone
led to reduced body weight of mice
(monitored twice weekly), which then
(independent of EPO) stayed at this
lower level compared with control mice
until cessation of cuprizone treatment
and returned to control values thereafter
(Figure 1B). Expectedly, the hematocrit
increased upon EPO treatment and re-
turned to the control range at 3 wks after
termination of EPO injections (Figure 1C).
Alleviation by EPO of the Detrimental
Effect of Toxic Demyelination on
Vestibulomotor Coordination and
Balance
Three-day rotarod tests immediately
upon cessation and 3 wks after cuprizone
feeding with or without EPO did not re-
veal any significant changes in gross
motor performance and motor learning
(Figures 1D, E). A more sensitive test of
motor coordination and vestibulomotor
function requiring interhemispheric com-
munication is the beam balance task
where mice have to cross two elevated
Figure 2. MRI of cuprizone-induced brain alterations and effect of EPO. (A) Presentation of
the %MTR as readout of myelination in the corpus callosum after 6 wks reveals reduction
by cuprizone and a trend of protection by EPO. (B) T2-weighted sample images of a con-
trol and a cuprizone-fed mouse after 6 wks illustrate brain/ventricle dimensions. Volumetri-
cal analyses of total brain volume (C) and of ventricles (D–F) show a clear effect of EPO
after 6 wks, but no longer after 9 wks. For all panels: n = 4–6 (respective n number is al-
ways given in the bar); mean ± SEM is presented.
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beams of 10 and 8 mm diameter, respec-
tively. After 6 wks of cuprizone, mice
needed significantly longer to cross the
10-mm as well as the 8-mm beam com-
pared with untreated control mice (P <
0.001). EPO treatment of cuprizone mice
improved performance compared with
placebo (Figure 1F). After 3 wks without
any treatment, all mice had reached a
similar performance, underlining the pro-
nounced spontaneous recovery after
cuprizone (Figure 1F).
Mitigation of Ventricular Enlargement
and Degree of Demyelination by EPO
After wk 6, the %MTR as a magnetic
resonance imaging (MRI) readout corre-
lating with myelination in the corpus
callosum (23) was lower in cuprizone-
treated mice, pointing to demyelination.
EPO tended to counteract this decrease.
After the 3-wk recovery period, there
was still a decrease of %MTR compared
with controls, but no measurable further
benefit of EPO treatment (Figure 2A).
Figure 2B illustrates typical T2-weighted
brain images of a control and a cupri-
zone-treated animal after 6 wks. Quan-
tification of total brain volume on the
basis of high-resolution T1 maps
showed an increase in cuprizone-fed
mice (P = 0.005), an effect mitigated by
EPO treatment at wk 6 (Figure 2C). This
increase is explained by the known
cuprizone-induced enlargement of the
whole ventricular system (left and right
lateral ventricle as well as third ventri-
cle) (24), which is  attenuated by EPO
(Figures 2D–F). Compared to the 6-wk
time point, all cuprizone-treated mice
displayed a pronounced spontaneous re-
covery at wk 9, with no further benefit
of EPO.
Attenuation by EPO of a Cuprizone-
Induced Increase in Microglial
Numbers and APP Accumulations as
Readout of Neuroinflammation and
Axonal Degeneration
To better understand the observed ef-
fects of EPO on behavioral and imaging
parameters after wk 6, we chose this time
point to investigate the number of oligo-
dendrocytes and microglia as well as the
degree of axonal degeneration within the
corpus callosum (anatomical overview of
screened regions in Figure 3A). The num-
ber of adult oligodendrocytes as stained
by CC-1 (anti-APC) was remarkably re-
duced upon cuprizone feeding (P < 0.001)
without any measurable benefit of EPO
(Figures 3B–D). Moreover, cuprizone re-
sulted in a significant increase in mi-
croglial numbers in the corpus callosum
(P < 0.001), an effect  diminished by EPO
treatment (Figures 3E–G). In addition, ax-
onal degeneration induced by cuprizone
within the corpus callosum, as quantified
by APP-positive axonal swellings, was at-
tenuated upon EPO (Fig ures 3H–J). Quan-
titative mRNA analysis of cytokines (IL-
1α, IL-1β, TGF-β) and microglia activity
markers (C1qA, Trem-2) yielded a signifi-
cant increase under cuprizone of the in-
flammation mediators IL-1α, IL-1β, C1qA
and Trem-2 and a significant decrease of
the protective growth factor TGF-β (all 
P < 0.05). EPO showed in several cases a
tendency in the respective other direction,
consistent with its counteraction of the
detrimental cuprizone effects. These EPO
Figure 3. Cuprizone-induced changes of oligodendrocyte and microglia numbers as well
as axonal degeneration in the corpus callosum: effect of EPO. All histological analyses pre-
sented have been performed after 6 wks of cuprizone ± EPO. (A) Anatomical overview of
screened corpus callosum regions. (B–D) Oligodendrocytes in the rostral and caudal corpus
callosum are massively reduced upon cuprizone; there was no effect of EPO (D: histologi-
cal sections with scale bar 50 μm). (E–G) Microglial numbers in the rostral and caudal cor-
pus callosum are highly increased, dampening effect of EPO (G: histological sections with
scale bar 50 μm). (H–J) APP-positive accumulations in the corpus callosum (J: histological
sections with accumulations indicated by arrows; scale bar 20 μm). For all panels: n = 7–11
(respective n number is always given in the bar); mean ± SEM is presented.
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trends, however, all failed to reach statisti-
cal significance (all P > 0.05) (Figure 4).
DISCUSSION
This study used the cuprizone model
of toxic demyelination to explore the
protective potential of EPO in the ab-
sence of T cell–mediated acute immune-
inflammatory processes. In this regard,
the model may simulate some aspects of
chronic progressive MS. Indeed, we
found neurological, imaging and histo-
logical evidence for a beneficial effect of
EPO in this condition.
The strong inflammatory component
in this model is reflected by the highly
increased numbers of microglia in the
corpus callosum, associated with APP-
positive accumulations as early signs of
axonal degeneration. APP accumulations
are likely the consequence of inflamma-
tion and are essentially absent in control
mice. Both readouts of damage have
been reported earlier in this model
(25–28) and were found here to be re-
duced by EPO treatment. This reduction
may at least partly explain the beneficial
effects of EPO on neurological/imaging
parameters (that is, vestibulomotor func-
tion and %MTR).
Attenuation by EPO treatment of mi-
croglial numbers and microglia-mediated
inflammation has been demonstrated
among others in models of cortical lesion
(29), EAE (5,11), epilepsy (30), closed head
injury (31) and ischemia (32) and has been
associated with improved clinical out-
come (11). In contrast, to our knowledge,
reduction of APP accumulations by EPO
has not been demonstrated yet. This latter
finding may be secondary to EPO-medi-
ated dampening of micro glial activation
and inflammation or be due to direct pro-
tective EPO effects on neurons/axons, in-
terrupting the vicious cycle of demyelina-
tion, inflammation, compromised axonal
metabolism and axonal degeneration.
Oligodendrocyte numbers were se-
verely diminished by cuprizone but, sur-
prisingly, no protective effects of EPO on
this cell type were found here. In other
models, a clear beneficial EPO effect on
oligodendrocyte numbers was demon-
strated (29,33). This discrepancy may be
explained by the time point or brain
 region of cell counting selected in the
present study or (more likely) by a mech-
anism of cell death that cannot be coun-
teracted by EPO. Interestingly, a recent
article reporting an advantageous influ-
ence of vitamin D on demyelination in
the cuprizone model, strikingly similar
to the results obtained here, also failed to
detect effects on oligodendrocytes (34).
The fact that both vitamin D and EPO act
via at least one common pathway, MAPK
(35), as well as seem to share mecha-
nisms or interact regarding iron absorp-
tion or metabolism (36,37), may make fu-
ture studies on a potential interplay of
these agents attractive.
The beam balance test turned out to be
a sensitive clinical test for measuring dis-
ability and neuroprotection by EPO in
the cuprizone model. Its performance ob-
viously requires a more sophisticated
function of neuronal networks in the
brain including interhemispheric com-
munication. In contrast, the rotarod was
used here as a crude motor control test,
indicating simpler and more elementary
functions. Not too surprising, it did not
show any evidence of compromised
function, an observation that had already
led other authors to develop more sensi-
tive tests for this model (38).
The cuprizone model has a number of
difficulties and limitations, some of
which have been mentioned in previous
reports (reviewed in [26] and [39]): (a) it
is variable, requiring relatively large
numbers of mice for solid conclusions;
(b) it is characterized by damage and re-
cuperation running in parallel, making
predictions of the right time point for
measurements difficult; (c) it shows a
rapid and remarkable spontaneous re-
covery after cessation of toxin feeding,
rendering it less suitable for extended
pharmacological neuroregeneration
studies; and (d) last but not least, the
mechanisms of damage by the copper
chelator cuprizone are still incompletely
characterized and subject to investiga-
tion (40). These difficulties and limita-
tions of the cuprizone model may ulti-
mately explain why our search for
Figure 4. Cuprizone-induced alterations in brain mRNA levels of cytokines and microglia
activity markers: effect of EPO. All qPCR analyses presented have been performed after 
6 wks of cuprizone ± EPO. Analyses of mRNA for cytokines (IL-1α, IL-1β, TGF-β) (A–C) and
microglia activity markers (C1qA, Trem-2) (D, E) yielded significant shifts under cuprizone
(all P < 0.05). EPO showed in several cases only a slight tendency in the respective other
direction (all P > 0.05). Expression levels are normed to the normalization factor (NF; i.e.
geometric mean of GAPDH, β-actin, and HPRT1 mRNA levels). For all panels: n = 5 –11;
mean ± SEM is presented. PL, placebo. 
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further mechanistic insight by quantifi-
cation of cytokines, known to be po-
tently influenced by EPO and/or cupri-
zone in other models (41–46), or of
microglial activity markers (46,47)
yielded tendencies at best, but no clear-
cut results.
CONCLUSION
To conclude, despite all the problems
connected with the cuprizone model,
there was a surprisingly clear protective
effect of EPO detectable, with not all
readouts reaching nominal significance
but essentially all parameters adding to
a mosaic: We suggest that EPO amelio-
rates neurological symptoms in the
cuprizone model of demyelination by
reduction of inflammation-associated
axonal degeneration in white matter
tracts. This effect of EPO may also par-
tially explain its beneficial action in
chronic progressive MS, and is worth-
while to pursue.
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